Mylan (NSDQ:MYL) posted first-quarter results today that missed the consensus revenue forecast on Wall Street, sending its share prices down.
The Canonsburg, Penn.-based company swung to red ink for the three months ended March 31, reporting losses of -$25 million, or -5¢ per share, on a -7.0% sales decline to $2.5 billion, compared with Q1 2018.
Adjusted to exclude one-time items, earnings per share were 82¢, 3¢ ahead of The Street, where analysts were looking for sales of $2.7 billion.
Get the full story on our sister site, Drug Delivery Business.
